新銳醫藥(06108.HK)接獲證監會向高院提交呈請 續停牌
新銳醫藥(06108.HK)公布,於11月17日公司獲送達由證監會向高等法院提交的呈請蓋印副本,除公司外,呈請中的其他兩名答辯人為兩名公司前董事,即周凌及戴海東,兩人已分別於2018年6月27日及2015年11月5日退任及辭任公司執行董事的職務。
證監會指稱,於2015至2018年期間,二人各自對公司的業務或事務負有全部或部分責任,並涉及對其或其成員或其任何部分成員的不法行為或其他不當行為,導致其成員或其任何部分成員未獲提供彼等可能合理預期獲得的關於其業務或事務的所有資料,及/或不公平地損害其成員或其任何部分成員。
公司正就呈請尋求法律意見,並將適時或按上市規則及或證券及期貨條例之規定作進一步公告。公司續停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.